



Completion of share buy-back programme

On 28 August 2023, Gubra A/S ("**Gubra**" or the "**Company**") announced resumption of its share buy-back programme of in total 27,271 shares. The purpose of the share buy-back programme is to meet the Company's obligations arising from its share-based incentive programmes to employees (Restricted Stock Units).

Today, Gubra announces the completion of the share buy-back programme. As 1,539 shares were repurchased during the period 30 June to 28 July, the remaining number of shares that have now been repurchased amounts to 25,692 (at a price of approximately DKK 2.8 million).

The details for each transaction made under the resumed share buy-back programme is attached to this announcement.

With the transactions carried out under the programme, Gubra owns a total of 59,271 own shares, corresponding to 0.4% of the share capital of the Company. The total amount of shares in the company is 16,349,703 including treasury shares.

Contacts at Gubra

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586

Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments

[Completion of share buy-back programme](#)

[Repurchase Of Shares 28 Aug 2023 10 Oct 2023](#)